Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR35 | Q9HC97 | 12/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.31 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.31 |
| ▸ | GRN | P28799 | 1/20 | 0.31 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22833101 | 0.80 | DAO (0.43) | GPR35GSK3BTSHRHSD17B10RXFP1 | |
| SCHEMBL25948660 | 0.76 | ALDH1A1 (0.39) | GPR35GSK3BTSHRCYP2C9 | |
| SCHEMBL1912332 | 0.73 | NPSR1 (0.41) | GPR35GSK3BNPSR1RXFP1 | |
| SCHEMBL3780362 | 0.70 | GPR35 (0.48) | GPR35GSK3BHSD17B10PKMNPSR1 | |
| SCHEMBL4264513 | 0.69 | GAA (0.44) | HSD17B10CYP2C9HIF1APKMUCHL1 | |
| SCHEMBL15878596 | 0.69 | GSK3B (0.61) | GPR35GSK3BPKMNPSR1RXFP1 | |
| SCHEMBL861282 | 0.68 | LCK (0.40) | — | |
| SCHEMBL14708715 | 0.67 | NPC1 (0.43) | TSHRHSD17B10NPSR1 | |
| SCHEMBL432666 | 0.67 | NR1I2 (0.39) | GPR35GSK3B | |
| SCHEMBL27416028 | 0.66 | GPR35 (0.40) | GPR35GSK3BPKMNPSR1RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8142909-B2 | Blue phosphorescent imidazophenanthridine materials | UNIVERSAL DISPLAY CORPORATION (US) | 2012-03-27 | — | — | US | disclosed |
| US-8142909-B2 | Blue phosphorescent imidazophenanthridine materials | UNIVERSAL DISPLAY CORPORATION (US) | 2012-03-27 | — | — | US | disclosed |
| WO-2008156879-A1 | BLUE PHOSPHORESCENT IMIDAZOPHENANTHRIDINE MATERIALS | UNIVERSAL DISPLAY CORPORATION (US) | 2008-12-24 | — | — | WO | disclosed |
| US-20080297033-A1 | BLUE PHOSPHORESCENT IMIDAZOPHENANTHRIDINE MATERIALS | UNIVERSAL DISPLAY CORPORATION | 2008-12-04 | — | — | US | disclosed |
| US-20080297033-A1 | BLUE PHOSPHORESCENT IMIDAZOPHENANTHRIDINE MATERIALS | UNIVERSAL DISPLAY CORPORATION | 2008-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080297033-A1 | BLUE PHOSPHORESCENT IMIDAZOPHENANTHRIDINE MATERIALS | IK, CRY1, MAP1LC3C | GPR35 1942/4885GSK3B 3899/4885TSHR 4444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.